Pour savoir comment effectuer et gérer un dépôt de document, consultez le « Guide abrégé – Dépôt de documents » sur le site Web de la Bibliothèque. Pour toute question, écrivez à corpus@ulaval.ca.
 

Personne :
Bansept, Marc-Antoine

En cours de chargement...
Photo de profil

Adresse électronique

Date de naissance

Projets de recherche

Structures organisationnelles

Fonction

Nom de famille

Bansept

Prénom

Marc-Antoine

Affiliation

Université Laval. Département de biochimie, de microbiologie et de bio-informatique

ISNI

ORCID

Identifiant Canadiana

ncf13699270

person.page.name

Résultats de recherche

Voici les éléments 1 - 1 sur 1
  • PublicationAccès libre
    A glycan-based plasmonic sensor for prostate cancer diagnosis
    (Royal Society of Chemistry, 2021-10-01) Lamarre, Mathieu; Bansept, Marc-Antoine; Boudreau, Denis; Tremblay, Thomas; Fradet, Vincent; Giguère, Denis; Robitaille, Karine
    Prostate cancer affects thousands of men who undergo clinical screening tests every year. The main biomarker used for the diagnosis of prostate cancer, prostate specific antigen (PSA), presents limitations that justify investigating new biomarkers to improve reliability. Antibodies against the tumor-associated carbohydrate antigen (Tn), or TACA, develop early in carcinogenesis, making them an interesting alternative as a target for prostate cancer diagnostics. In this work, the Tn antigen was synthesized and immobilized on a surface plasmon resonance sensor coated with a polydopamine/polyethylene oxide mixed layer used both as an anchoring surface for Tn capture moieties and to minimize surface fouling. The sensor could be regenerated and reused at least 60 times without any significant loss in sensitivity. Anti-Tn antibodies were detected in the 0-10 nM concentration range with detection limits of 0.1 and 0.3 nM in spiked buffer solutions and diluted human blood serum samples, respectively. Finally, as a proof-of-concept, this carbohydrate-based sensor was used to successfully discriminate blood serum samples from prostate cancer-free and prostate cancer patients.